Vibostolimab (MK-7684A)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Vibostolimab (MK-7684A), covering 2026-08-28 to 2026-08-28. Get the full timeline:
Most recent: Clinical Trial Update: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) [Phase 3]